Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 27;28(2):1094–1113. doi: 10.3390/curroncol28020106

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Comparative safety in terms of the incidence of ≥ grade 3 diarrhea between ICIs+EP (combined population of the treated groups of Atz+EP, Dur+EP, and Pem+EP) and EP, between ICIs+EP and IP, and between ICIs+EP and AP, for previously untreated ES-SCLC. Comparisons are shown as ICIs+EP vs. CT (EP, IP, or AP). Data are expressed as RR and 95% CrI. ICIs+EP, immune checkpoint inhibitors plus platinum–etoposide; Atz+EP, atezolizumab plus platinum–etoposide; Dur+EP, durvalumab plus platinum–etoposide; Pem+EP, pembrolizumab plus platinum–etoposide; EP, platinum–etoposide; IP, platinum–irinotecan; ES-SCLC, extensive-stage small cell lung cancer; CT, chemotherapy; RR, risk ratio; CrI, credible interval.